STRO
SUTRO BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$9.94
+4.52%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$10.05
From 52W high−75.70%
Volume158464.00
Market cap$164.82M
P/E (TTM)—
P/S (TTM)3.6x
Div yield—
Key dataNov 4, 2026
Open
$10.05
From 52W high
−75.70%
Volume
158464.00
Market cap
$164.82M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
30.0
MomentumView details →
1D Return
+4.52%
YTD Return
−17.89%
SummaryUpdated Jun 1, 2026
Sutro Biopharma, Inc. (NASDAQ:STRO) is a clinical-stage biotechnology company founded in 2003 and headquartered in South San Francisco, California. Originally incorporated as Fundamental Applied Biology, Inc., the company went public in September 2018. Sutro specializes in developing protein therapeutics for cancer and autoimmune disorders using its proprietary cell-free protein synthesis platform called XpressCF+. The company focuses on creating antibody-drug conjugates (ADCs) and other targeted therapies, with multiple drug candidates currently in clinical trials.
Similar companies
Latest newsMore news →
SUTRO BIOPHARMA, INC. announced that the first patient had been dosed in its Phase 1 trial of STRO-006 in patients with advanced solid tumors.14d agoSutro Biopharma reported Q2 2026 revenue of $9.8 million, down from $63.7 million in Q2 2025, with a net loss of $38.5 million and diluted EPS of -$2.33.85d ago